Long-term treatment for children with atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study is a follow-up for children who have already completed the first 18 weeks of treatment with the study medicine for atopic dermatitis (also called eczema). It tests whether the medicine continues to be safe and effective over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have already taken part in the main study and completed the 18-week check-up.
- You must be willing to sign a consent form to continue in this longer study.
- You must be able to communicate with the research team and attend follow-up visits.
- Your child cannot have any major surgery planned during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
This study looks at how long people with moderate to severe eczema stay on newer targeted medicines (biologics or pills). By reviewing medical records, researchers hope to learn which treatments work best over time and how they are used in real life.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.